Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.

Also called NCT02836704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 892 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02836704
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02836704. Randomized; no masking; primary purpose treatment. Start 2016-09-09 (actual); primary completion 2018-04-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
INSULIN GLARGINE
Intervention (Drug)
metformin
Intervention (Drug)
acarbose
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02836704
Content hash
c94926d675ec3d5ae150471faabd53221b440cb360848ed48c5bfeddbbe6ab78